Astrazeneca PLC (Spons. ADRs)
[WKN: 886715 | ISIN: US0463531089]
Aktienkurse
65,670$ 2,20%
Echtzeit-Aktienkurs Astrazeneca PLC (Spons. ADRs)
Bid: Ask:
Reuters Kategorien
dpa-AFX Compact / dpa-AFX PRO Kategorien
Traderfox: dpa-AFX ProFeed Kategorien
dpa-AFX ProFeed Kategorien

AstraZeneca licenses lipid lowering Lp(a) asset

7 October 2024 AstraZeneca strengthens its cardiovascular pipeline with agreement for a pre-clinical novel lipid-lowering therapy AstraZeneca has entered into an exclusive…

Total Voting Rights

1 October 2024 15:00 BST Transparency Directive Voting rights and capital The following notification is made in accordance with the UK Financial Conduct…

Tagrisso US approval in unresectable lung cancer

26 September 2024  Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer Based on LAURA Phase III trial results which showed Tagrisso extended…

Final OS results reported for TROPION-Breast01

23 September 2024 Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase…

FASENRA EGPA US FDA APPROVAL

18 September 2024 Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis New indication supported by the MANDARA trial which showed…

AstraZeneca: Upgrade

Wien (www.aktiencheck.de) - Rating-Update: Hans Engel, Analyst von Erste Group Research, stuft die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455,…

AstraZeneca: Herabstufung

Stockholm (www.aktiencheck.de) - Rating-Update: Die Analysten von Nordea stufen die Aktie von AstraZeneca plc (ISIN: GB0009895292, WKN: 886455, Ticker-Symbol: ZEG, London…

GOLDMAN SACHS stuft ASTRAZENECA auf Buy

NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für Astrazeneca mit einem Kursziel von 15914 Pence…

AstraZeneca Overweight

NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Auf…